We use tools, such as cookies, to enable essential services and functionality on our site. We also use this to collect data on how our visitors interact with our site, products and services. By clicking accept, you agree to our use of these tools for advertising, analytics and support. I Accept Privacy Policy Cookie Policy

immunodiagnosticsystems
0
immunodiagnosticsystems
0
  • About IDS
    • Company Overview
    • Corporate History
    • Strategic Vision
    • Board of Directors
    • IDS Worldwide
    • IDS Values
    • Careers
    • News and Events
  • Products
    Automated
    Manual
  • Instrumentation
    • IDS-iSYS Multi-Discipline Automated System
    • Specifications
    • Service & Support
  • Clinical Areas
    Bone Metabolism
    Calcium Metabolism
    CKD-MBD
    Growth
    Cartilage Markers
    Fertility
    Autoimmunity
    Infectious Diseases
    Allergy
    Covid-19
    Sarcoidosis Assays
    Therapeutic Drug Monitoring
    Hypertension Immunoassays
  • Research Areas
    Animal Research
    Bone Turnover Markers
    Other Research Areas
  • COVID-19 Tests
  • Investor Relations
  • Contact
immunodiagnosticsystems
+44 (0)191 5190660
0

Quotes

  • About IDS
    • Company Overview
    • Corporate History
    • Strategic Vision
    • Board of Directors
    • IDS Worldwide
    • IDS Values
    • Careers
    • News and Events
  • Products
    Automated
    Manual
  • Instrumentation
    • IDS-iSYS Multi-Discipline Automated System
    • Specifications
    • Service & Support
  • Clinical Areas
    Bone Metabolism
    Calcium Metabolism
    CKD-MBD
    Growth
    Cartilage Markers
    Fertility
    Autoimmunity
    Infectious Diseases
    Allergy
    Covid-19
    Sarcoidosis Assays
    Therapeutic Drug Monitoring
    Hypertension Immunoassays
  • Research Areas
    Animal Research
    Bone Turnover Markers
    Other Research Areas
  • COVID-19 Tests
  • Investor Relations
  • Contact

Month: July 2007

  • All News
  • Company News
  • Event News
  • Industry News
  • Product News
Two IDS members inspect assays

Completion of Acquisition – Nordic Bioscience Diagnostics

IDS, a leading producer of diagnostic testing kits, announces the completion of the acquisition of 100% of the ordinary share capital of Nordic Bioscience Diagnostics A/S (NBD). As previously announced, the consideration for NBD was £17,000,000, with £10,000,000 (€14,900,000) to be satisfied in cash, and the balance satisfied through the issue of 2,783,300 new Ordinary […]

Leaves against a sunny sky

Proposed Acquisition

IDS, a leading producer of diagnostic testing kits, announces the completion of the acquisition of 99.93% of the ordinary share capital of Biocode Hycel S.A. (Biocode). As previously announced, the initial consideration for Biocode was €23,000,000, with €11,000,000 to be satisfied in cash, and the balance satisfied through the issue of 2,839,719 new Ordinary Shares […]

  • About Us
  • Products
  • Instrumentation
  • Clinical Areas
  • Research Areas
  • Investor Relations
  • Contact
Connect with us
Connect with us
Connect with us
  • Careers
  • News & Events
  • Sitemap
  • Cookie Policy
  • Terms of Use Policy
  • Privacy Policy
  • Acceptable Use Policy
  • Purchasing T&Cs
  • Terms of Sale
IDS PLC © 2017 Immunodiagnostic Systems. All Rights Reserved. IDS is a listed company, traded on the Alternative Investment Market (AIM; trading symbol IDH) of the London Stock Exchange. Please note our sites uses cookies for content personalisation, please review our cookie policy for further information.

To receive our Newsletter Document Name, please provide us with your following details:

To receive our Newsletter, please provide us with your following details: